CRCM  Vol.3 No.5 , May 2014
Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforation―A Case Report
Abstract: We report the case of a 63-year-old male with an inoperableT4N1 adenocarcinoma of colon, K-RAS mutant, who received first line chemotherapy with capecitabine and oxaliplatin. A CT scan following 4 cycles demonstrated progressive disease, and second line therapy with capecitabine, irinotecan and bevacizumab was commenced. CT scans at 3 and 6 months during this treatment regime demonstrated radiologically stable disease, and therefore the treatment was continued. The patient developed nasal septal perforation, a rare but recognised complication of bevacizumab therapy, which was managed conservatively. Here we highlight that no consensus exists on whether bevacizumab should be continued in this situation. After a detailed discussion about the risks and benefits, this patient continued on with the same therapeutic regime. However, eight weeks later, this patient then developed a localised tumour perforation, necessitating an emergency admission to his local hospital. We recommend caution in continuing bevacizumab in patients with colorectal cancer following a nasal septal perforation and advise a detailed discussion of risk with the patient, especially when the primary tumour remains in-situ.
Cite this paper: Nelmes, D. and Gwynne, S. (2014) Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforation―A Case Report. Case Reports in Clinical Medicine, 3, 319-321. doi: 10.4236/crcm.2014.35070.

[1]   Ellis, L.M. (2006) Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer. Seminars in Oncology, 33, S1-S7.

[2]   Whyte, S., Pandor, A. and Stevenson, M. (2012) Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics, 30, 1119-1132.

[3]   Mailliez, A., et al. (2010) Nasal Septum Perforation: A Side Effect of Bevacizumab Chemotherapy in Breast Cancer Patients. British Journal of Cancer, 103, 772-775.

[4]   Ramiscal, J.A. and Jatoi, A. (2011) Bevacizumab-Induced Nasal Septal Perforation: Incidence of Symptomatic, Confirmed Event(s) in Colorectal Cancer Patients. Acta Oncologica, 50, 578-581.

[5]   Mailliez, A., et al. (2010) Nasal Septum Perforations: A Side Effect of the Association of Bevacizumab and Taxanes in Patients with Breast Cancer? ASCO Meeting Abstracts, 28, 671.

[6]   Hapani, S., Chu, D. and Wu, S. (2009) Risk of Gastrointestinal Perforation in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. The Lancet Oncology, 10, 559-568.

[7]   Hompes, D. and Ruers, T. (2011) Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer. European Journal of Surgical Oncology (EJSO), 37, 737-746.

[8]   Van Cutsem, E., et al. (2009) Safety and Efficacy of First-Line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study. Annals of Oncology, 20, 1842-1847.

[9]   Kozloff, M., et al. (2009) Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. The Oncologist, 14, 862-870.

[10]   Poultsides, G.A., et al. (2009) Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy without Surgery as Initial Treatment. Journal of Clinical Oncology, 27, 3379-3384.